# Clinical Core

> **NIH NIH P30** · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $871,928

## Abstract

Massachusetts Alzheimer’s Disease Research Center: Clinical Core
The Mission of the MADRC Clinical Core parallels that of our Center as a whole: to detect clinically
meaningful changes in cognition and function in culturally, linguistically, and educationally diverse
older participants whose cognition ranges from normal to dementia, and who have syndromic Alzheimer’s,
Lewy Body Dementia (LBD), or Frontotemporal Dementia (FTLD). We aim at integrating standard and novel
clinical measures with advanced imaging and fluid biomarker data to evaluate clinical progression in the
context of disease markers, in order to accurately predict future trajectories. To accomplish these goals, we
have three Aims. Aim 1 CONTRIBUTES to the Center’s ability to carry out clinical research on Alzheimer's
Disease and Related Disorders (ADRD), focusing on developing and maintaining a diverse Research Cohort of
men and women with enhanced recruitment of our prioritized minority participants (Black or African American
and Hispanic), facilitating the collection of neuroimaging studies and fluid biomarkers, and developing a
protocol for disclosure of research findings. Aim 2, DEVELOPS new strategies, focusing on achieving universal
deep phenotyping of our Research Cohort and developing and testing novel clinical instruments, with an
emphasis on digital methods, for early disease detection and tracking of minimum clinically meaningful change
that can readily translate into primary care and community-based settings. We will also work closely with the
newly created MassGeneral Brigham Alzheimer Therapeutic program – a centralized program focused on
equitable access and monitoring of all patients undergoing newly FDA-approved medications for AD in our
institution– to implement standard UDS and validated novel measures in those patients. We will continue to
share our data and discoveries with other ADRCs and the broader scientific community for validation and
implementation. Aim 3 TRAINS clinical fellows and offers immersive experiences of clinical ADRD to REC
trainees in clinical diagnosis and provides cutting-edge training in clinical research methods. Aim 4
DIVERSIFIES the Clinical Core staff and Research Cohort participants by fostering recruitment, training, and
retention of diverse staff, and fully engaging and facilitating access to our growing minority participants and
their local communities to all research, education, and treatment and prevention efforts on ADRD. Overall, our
ultimate goal is to engage and promote equity across all stakeholders - patients, caregivers, clinicians and
researchers- as direct partners to accelerate toward a cure for ADRD.

## Key facts

- **NIH application ID:** 10864396
- **Project number:** 2P30AG062421-06
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Alberto Serrano-Pozo
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $871,928
- **Award type:** 2
- **Project period:** 2019-05-15 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10864396

## Citation

> US National Institutes of Health, RePORTER application 10864396, Clinical Core (2P30AG062421-06). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10864396. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*